UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

The lancet oncology, 2017-05, Vol.18 (5), p.631-639

2017

Volltextzugriff (PDF)

A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study)

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (3), p.454-462

2022

Volltextzugriff (PDF)

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer

Annals of surgical oncology, 2020-02, Vol.27 (2), p.460-467

2020

Volltextzugriff (PDF)

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer

Cancer science, 2020-05, Vol.111 (5), p.1676-1684

2020

Volltextzugriff (PDF)

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Investigational new drugs, 2015-06, Vol.33 (3), p.740-750

2015

Volltextzugriff (PDF)

Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer

Anticancer research, 2018-10, Vol.38 (10), p.5859-5866

2018

Volltextzugriff (PDF)

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)

Esophagus : official journal of the Japan Esophageal Society, 2021-10, Vol.18 (4), p.835-843

2021

Volltextzugriff (PDF)

Phase I/II trial of 2‐weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807)

Cancer science, 2014-09, Vol.105 (9), p.1189-1195

2014

Volltextzugriff (PDF)

A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study

International journal of clinical oncology, 2021-04, Vol.26 (4), p.701-707

2021

Volltextzugriff (PDF)

Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer

Anticancer research, 2020-04, Vol.40 (4), p.2247-2255

2020

Volltextzugriff (PDF)

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study

Ecancermedicalscience, 2018-07, Vol.12, p.847-847

2018

Volltextzugriff (PDF)

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study

Cancer science, 2018-03, Vol.109 (3), p.785-793

2018

Volltextzugriff (PDF)

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2015-10, Vol.18 (4), p.824-832

2015

Volltextzugriff (PDF)

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

Cancer science, 2019-03, Vol.110 (3), p.1032-1043

2019

Volltextzugriff (PDF)

Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A128 and/or UGT1A16 polymorphisms

Cancer science, 2011-10, Vol.102 (10), p.1868-1873

2011

Volltextzugriff (PDF)

Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018-11, Vol.21 (6), p.1050-1057

2018

Volltextzugriff (PDF)

Effect of Preadsorption of Organic Additives on the Appearance and Morphology of Electrogalvanized Steel Sheets

ISIJ International, 2014/07/15, Vol.54(7), pp.1653-1660

2014

Volltextzugriff (PDF)

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer

Cancer science, 2019-11, Vol.110 (11), p.3565-3572

2019

Volltextzugriff (PDF)

Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma

Japanese journal of clinical oncology, 2021-06, Vol.51 (6), p.911-917

2021

Volltextzugriff (PDF)

Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807

Esophagus : official journal of the Japan Esophageal Society, 2023-04, Vol.20 (2), p.272-280

2023

Volltextzugriff (PDF)

The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909

Esophagus : official journal of the Japan Esophageal Society, 2020-10, Vol.17 (4), p.417-424

2020

Volltextzugriff (PDF)

Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy

Cancer chemotherapy and pharmacology, 2017-10, Vol.80 (4), p.807-813

2017

Volltextzugriff (PDF)

Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma

Japanese journal of clinical oncology, 2013-06, Vol.43 (6), p.608-615

2013

Volltextzugriff (PDF)

Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2013-04, Vol.16 (2), p.261-267

2013

Volltextzugriff (PDF)

1 – 25 von 522

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(324)
Mit Volltextzugriff
(434)

Publikationsform

Sprache

Englisch
(465)
Japanisch
(200)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(241)
Life Sciences & Biomedicine
(151)
Humans
(130)
Male
(91)
Female
(86)
Oncology
(86)
Middle Aged
(81)
Aged
(76)
Physical Sciences
(65)
Adult
(63)
Technology
(62)
Chemotherapy
(53)
Engineering
(47)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(44)
Biological And Medical Sciences
(38)
Retrospective Studies
(38)
Treatment Outcome
(36)
Navigation
(35)
Medicine
(33)
Medicine & Public Health
(33)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study)

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)

Phase I/II trial of 2‐weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807)

A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study

Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A128 and/or UGT1A16 polymorphisms

Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan

Effect of Preadsorption of Organic Additives on the Appearance and Morphology of Electrogalvanized Steel Sheets

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer

Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma

Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807

The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909

Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy

Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma

Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment

Suchergebnisse filtern